- Home
- DSL vs XNCR Comparison
DSL vs XNCR Comparison
Compare DSL & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DSL | XNCR |
|---|---|---|
| Founded | 2013 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.1B |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | DSL | XNCR |
|---|---|---|
| Price | $11.16 | $16.00 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $22.78 |
| AVG Volume (30 Days) | 784.6K | ★ 838.7K |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 11.81% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $150,132,000.00 |
| Revenue This Year | N/A | $18.81 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 38.16 |
| 52 Week Low | $10.58 | $6.92 |
| 52 Week High | $12.92 | $24.94 |
Technical Indicators
Market Signals| Indicator | DSL | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 34.50 | 49.23 |
| Support Level | $11.12 | $16.44 |
| Resistance Level | $11.23 | $17.18 |
| Average True Range (ATR) | 0.08 | 0.95 |
| MACD | 0.01 | -0.29 |
| Stochastic Oscillator | 22.22 | 19.76 |
Price Performance
Historical ComparisonAbout DSL DoubleLine Income Solutions Fund of Beneficial Interests
DoubleLine Income Solutions Fund is a closed-end management investment company. Its primary investment objective is to seek high income and its secondary objective is to seek capital appreciation. It invests in debt securities and other income-producing investments anywhere in the world, including emerging markets. The company's investment portfolio comprises foreign corporate bonds, U.S. corporate bonds, bank loans, collateralized loan obligations, non-agency commercial mortgage backed obligations, asset-backed obligations, and municipal bonds among others.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.